Crescent Biopharma

CBIO (NasdaqCM)

Crescent Biopharma, Inc. is a U.S. biotechnology company developing cancer therapies. Its lead program, CR-001, is a proprietary anti–PD-1/anti–VEGF bispecific antibody in Phase 3 for solid tumors. It also has CR-002 and CR-003 in its pipeline. Crescent partners with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology treatments. Formerly GlycoMimetics, it was founded in 2024 and is headquartered in Waltham, Massachusetts.